
Many phase III trials presented at annual meetings of the American Society of Clinical Oncology zzso remain zzso The results of these unpublished trials, if more generally known, might have an impact on clinical zzso 

zzso of large phase III trials evaluating systemic cancer treatment were identified from conference proceedings of the 1989 to 2003 zzso annual zzso zzso zzso and zzso were searched for corresponding zzso A compendium of unpublished phase III trials was zzso Clinical significance of zzso was determined by disease zzso zzso experts from two academic cancer centers in zzso 

A total of zzso phase III trials were identified of which 66 zzso remain without a subsequent publication at a minimum of zzso years of follow-up and 94 zzso were published after a delay of zzso 5 years from their initial zzso Of the unpublished trials, zzso were presented as oral sessions at an zzso meeting, and zzso of the abstracts reported negative zzso The experts judged that zzso of the unpublished trials addressed an important question and 59% might have had clinical impact if their results had been published zzso 

A substantial number of cancer clinical trials with potential influence on clinical practice remain unpublished and many other trials are published after a substantial zzso zzso of clinical trials breaks an implicit contract with participants, institutional review zzso and zzso 

